Palisade Bio (NASDAQ:PALI) Releases Quarterly Earnings Results, Hits Expectations

Palisade Bio (NASDAQ:PALI) posted its earnings results on Monday. The company reported ($0.05) EPS for the quarter, meeting analysts’ consensus estimates of ($0.05), FiscalAI reports. The business had revenue of $0.50 million for the quarter.

Palisade Bio Stock Performance

Shares of PALI traded down $0.10 during trading hours on Wednesday, hitting $2.04. 319,869 shares of the stock were exchanged, compared to its average volume of 3,803,516. The stock’s 50-day moving average price is $1.94 and its two-hundred day moving average price is $1.91. Palisade Bio has a 12-month low of $0.53 and a 12-month high of $2.86. The company has a market cap of $354.97 million, a price-to-earnings ratio of -2.02 and a beta of 1.52.

Wall Street Analysts Forecast Growth

Several brokerages have commented on PALI. HC Wainwright reissued a “buy” rating and issued a $2.00 price objective on shares of Palisade Bio in a report on Tuesday, June 30th. Weiss Ratings downgraded Palisade Bio from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, July 14th. Oppenheimer began coverage on Palisade Bio in a research report on Thursday, July 23rd. They set an “outperform” rating and a $8.00 target price on the stock. Wall Street Zen raised shares of Palisade Bio from a “sell” rating to a “hold” rating in a research note on Saturday, July 25th. Finally, LADENBURG THALM/SH SH raised shares of Palisade Bio to a “strong-buy” rating in a report on Thursday, June 25th. Two analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus price target of $9.00.

Insider Buying and Selling at Palisade Bio

In other Palisade Bio news, Director Robert Jr. Baltera bought 30,000 shares of the stock in a transaction on Tuesday, July 7th. The shares were bought at an average price of $2.03 per share, with a total value of $60,900.00. Following the purchase, the director directly owned 416,904 shares in the company, valued at $846,315.12. This trade represents a 7.75% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Mitchell Lawrence Jones sold 51,880 shares of the company’s stock in a transaction on Tuesday, July 7th. The stock was sold at an average price of $2.05, for a total transaction of $106,354.00. Following the sale, the insider directly owned 94,009 shares of the company’s stock, valued at $192,718.45. The trade was a 35.56% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last 90 days, insiders have bought 125,000 shares of company stock worth $250,100. Corporate insiders own 0.07% of the company’s stock.

Institutional Trading of Palisade Bio

Large investors have recently bought and sold shares of the business. Virtu Financial LLC acquired a new stake in Palisade Bio in the 4th quarter valued at about $28,000. Creek Drive Management Group LLC acquired a new position in shares of Palisade Bio during the 4th quarter worth approximately $723,000. XTX Topco Ltd grew its position in shares of Palisade Bio by 53.8% in the fourth quarter. XTX Topco Ltd now owns 21,669 shares of the company’s stock valued at $51,000 after purchasing an additional 7,584 shares in the last quarter. Ikarian Capital LLC purchased a new stake in shares of Palisade Bio in the fourth quarter valued at approximately $646,000. Finally, Squadron Capital Management LLC acquired a new stake in shares of Palisade Bio in the fourth quarter valued at approximately $10,575,000. Hedge funds and other institutional investors own 11.79% of the company’s stock.

About Palisade Bio

Palisade Bio, Inc is a clinical‐stage biotechnology company focused on pioneering localized immunotherapies for the treatment of cancer and inflammatory diseases. The company leverages a proprietary prodrug platform designed to activate therapeutic agents selectively within the tumor microenvironment or sites of inflammation. Its core strategy centers on stimulating the innate immune system via toll‐like receptor 9 (TLR9) agonism to drive targeted immune responses while minimizing systemic exposure and toxicity.

The company’s lead product candidate, PDS0108, is an intratumoral TLR9 agonist prodrug currently in Phase 1/2 clinical trials for patients with advanced solid tumors.